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Backgrounds: Efficacy of gefitinib therapy strongly depends on
epidermal growth factor receptor (EGFR)-mutation status in Asian
patients with non-small cell lung cancer. Recently, the survival
advantage of erlotinib, another tyrosine kinase inhibitor, was not
affected by EGFR mutation status in a phase III trial, indicating that
patients with EGFR-wild-type (EGFR-wt) tumors might also benefit
from this tyrosine kinase inhibitor. The aim of this trial was to
evaluate the efficacy and toxicity of erlotinib in Japanese patients
with EGFR-wt tumors.
Methods: The primary end point was an objective response. Patients
with EGFR-wt tumors previously receiving one to three chemother-
apy regimens were enrolled in this trial. The mutation status was
assessed using the peptide nucleic acid-locked nucleic acid poly-
merase chain reaction clamp method. Erlotinib was administered
(150 mg/d) until disease progression or unacceptable toxicities
occurred.
Results: Thirty patients were enrolled between January and Decem-
ber 2008. Objective response was observed in one patient (3.3%),
and the disease became stable in 18 patients (60.0%). Skin rash was
the most common side effect. Grades 3–4 adverse events included
pulmonary embolism, keratitis, and anemia. Two other patients
developed interstitial lung disease (grades 1 and 2). Nevertheless, all
these events were reversible, resulting in no treatment-related
deaths. With a median follow-up time of 10.7 months, the median
survival time and median progression-free survival times were 9.2
and 2.1 months, respectively.
Conclusion: This is the first prospective biomarker study showing
that erlotinib therapy for pretreated patients with EGFR-wt tumors
seems to have a modest activity with no irreversible toxicity.
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The recent advent of the epidermal growth factor receptortyrosine kinase inhibitors (EGFR-TKIs), gefitinib and
erlotinib, has revitalized interest in the treatment of advanced
non-small cell lung cancer (NSCLC) because of their new
and distinct mechanism of action compared with cytotoxic
agents. Several phase III trials of gefitinib and erlotinib in
relapsed patients with NSCLC have been conducted, show-
ing a similar survival benefit compared with docetaxel in
the gefitinib studies,1 whereas the erlotinib study demon-
strated a significant survival advantage over the best sup-
portive care alone.2
Recently, as a molecular oncologic alteration, somatic
mutations in the tyrosine kinase domain of the EGFR gene
have been found in patients with NSCLC as gain-of-function
oncogenic mutations.3 The association between the EGFR
gene mutation status and responsiveness to gefitinib has been
extensively studied, especially in Asian patients with
NSCLC, mainly because of the high frequency of EGFR-
mutation rates in populations of Asian origin. We and other
investigators demonstrated retrospectively and prospectively
that EGFR-mutant (EGFR-mt) tumors yielded a high sensi-
tivity to gefitinib as observed in clinical studies (response rate
of around 75% and median progression-free survival PFS
time of 9.7 months).4,5 In contrast, Asian patients with no
active EGFR-mt tumors (n  176) were unlikely to benefit
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from the first-line use of TKI, with a response rate of only
1.1% and median PFS time of less than 2 months.6
Despite such a great difference in the sensitivity to
gefitinib in patients with EGFR-mt tumors and those with
EGFR-wild-type (EGFR-wt) tumors, the survival impact of
erlotinib monotherapy was not confounded significantly by
mutation status in the recent subanalysis of the BR.21 trial.7
The analysis showed that hazard ratios of erlotinib therapy
over placebo were 0.55 and 0.74 in patients with and without
EGFR-mt tumors (n  34 and 170), respectively, and sur-
prisingly, its interaction was not significant (p  0.47). This
indicates that erlotinib therapy might be also beneficial in
terms of survival irrespective of EGFR-mutation status.
In addition, pemetrexed, one of the standard treatments
for relapsed patients with NSCLC,8 has not yet been ap-
proved by the Japanese government, and few agents are
available in the salvage setting in Japan. Based on this
hypothesis and background, we conducted a phase II trial of
erlotinib monotherapy in Japanese patients with relapsed
NSCLC who did not possess active EGFR mutations. The
aim of this trial was to evaluate the efficacy and toxicity of
erlotinib and then assess whether this agent should be eval-
uated in a further phase III trial for patients without EGFR-mt
tumors.
PATIENTS AND METHODS
Eligibility Criteria
Patients were required to fulfill the following eligibility
criteria: pathologically proven NSCLC, measurable tumor
sites, Eastern Cooperative Oncology Group performance sta-
tus of 0 to 2, tumors without EGFR mutations (exons 18, 19,
20, and 21), history of one to three prior systemic chemo-
therapy regimens but no prior EGFR-TKI therapy, ineligibil-
ity as candidates for curative treatment (stage IIIB/IV), ap-
propriate organ function, and acquisition of written informed
consent. Patients receiving systemic anticancer therapy
within 4 weeks of proposed entry to this trial were excluded.
Baseline pretreatment evaluations included a com-
plete history, physical examination, laboratory tests, a
chest radiograph, and a computed tomography (CT) scan
of the chest. Additionally, a CT scan of the abdomen,
magnetic resonance imaging of the brain, and a radionuclide
bone scan were considered if medically indicated. Positron
emission tomography/CT was also used for staging in some
cases. The baseline CT scan should have taken within 4
weeks before the registration.
The two-step protocol of this phase II study, including
testing for EGFR mutations using the peptide nucleic acid-
locked nucleic acid polymerase chain reaction clamp method,
and administering erlotinib to patients with NSCLC who had
EGFR-wt tumors, was approved by the institutional review
boards of the participating institutes. This study was per-
formed in accordance with the Declaration of Helsinki (1964,
amended in 2000) of the World Medical Association. All
enrolled patients gave their written informed consents.
Assessment of Tumor EGFR-Mutation Status
The peptide nucleic acid-locked nucleic acid polymer-
ase chain reaction clamp assay for EGFR mutations can
quickly detect a total of 13 known alterations in a target
region. This method has been described in detail,9 and EGFR
mutations could be detected in the presence of 100-fold to
1000-fold wild-type EGFR background molecules. In Japan,
this detection method has been commercially available. The
13 variations consist of 7 exon 19 deletions (E746-A750del
nt 2235–2249, E746-A750del nt 2236–2250, L747-
A750delT751S, L747-S752delP753S, L747-E749delA750P,
L747-S752delE746V, and S752-I 759del), 2 exon 21 muta-
tions (L858R and L861Q), 3 exon 18 mutations (G719C,
G719S, G719A), and 1 exon 20 mutation (T790M).
Assessments of Toxicity and Antitumor Activity
All toxicities were graded according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events v3.0. The standard Response Evaluation Criteria in
Solid Tumors was used to evaluate responses. The CT scan
for the assessment of target or nontarget lesion was designed
to be done every 4 weeks. Complete and partial responses
were confirmed by two observations not less than 4 weeks
apart. A determination of stable disease required disease
stabilization for at least 6 weeks.
Treatment Schedules and Modifications
Erlotinib was administered orally at a daily dose of 150
mg. Erlotinib treatment was interrupted or a dose reduction
was considered if any patient developed grade 3 nonhemato-
logical toxicities or grade 1 pneumonitis/pulmonary infil-
trates. Erlotinib treatment was discontinued if a patient met
any of the following conditions: disease progression; patient
withdrawal of informed consent; development of grade 4
nonhematological toxicity or grade 2 pneumonitis/pulmonary
infiltrates; or no improvement of grade 3 nonhematological
toxicities or grade 1 pneumonitis/pulmonary infiltrates after
treatment interruption for 4 weeks. No other systemic anti-
cancer treatment was permitted during the trial.
Statistical Considerations
This trial was designed to assess the response rate for
erlotinib monotherapy as a primary end point. Secondary end
points were toxicity, PFS, and overall survival. A Minimax
two-stage design10 was used to test whether sufficient evi-
dence was found to determine that a response rate was at least
20% (i.e., clinically feasible) versus at most 5% (i.e., clini-
cally infeasible), accepting a false-positive rate () of 5%
and a false-negative rate () of 20%. In this two-stage
design, accrual was stopped with a first stage of 13 patients if
no patients responded to the treatment. Otherwise, it was
continued to a total of 27 patients, declaring that erlotinib
treatment was effective if four or more patients had an
objective response. With an assumed dropout rate of 10%, the
number of patients needed was 30.
Yoshioka et al. Journal of Thoracic Oncology • Volume 5, Number 1, January 2010
Copyright © 2009 by the International Association for the Study of Lung Cancer100
RESULTS
Patient Characteristics, Specimens, and
Treatment Delivery
Thirty patients with relapsed NSCLC were enrolled
between January and December 2008 at six institutes in Japan
(Table 1). Most of the patients were male smokers who had
a good performance status, adenocarcinoma histology, and no
prior pulmonary comorbidity. The median number of prior
chemotherapy regimens administered was two, and the plat-
inum-based regimens were the most frequently used (22
patients; 73%).
Specimens were obtained from patients who gave their
written informed consent. Samples obtained before the initi-
ation of erlotinib treatment included 13 transbronchial biop-
sies, five needle biopsies, 12 surgical biopsy specimens, and
they were a portion of the samples obtained to establish the
diagnosis of NSCLC.
Treatment Delivery
Median treatment duration was 33 days with a range
of 4 to 132 days. Treatment was interrupted in 11 patients
(37%), mainly due to adverse events (skin rash in nine
patients, nausea/vomiting in one, and transient dyspnea
sense (shortness of breath) in one). The median duration of
treatment interruption was 10 days. In 10 patients (33%),
the treatment dose was reduced to 100 mg/d in six patients,
75 mg/d in two patients, and 50 mg/d in two patients
because of adverse events (skin rash in nine patients and
nausea/vomiting in one). All these adverse events were
reversibly improved with the above-mentioned treatment
interruption or dose reduction. At the time of study anal-
ysis, treatment was discontinued in 29 patients because of
disease progression in 24 patients, adverse events in four
(interstitial lung disease ILD in two patients, keratitis in
one, and pulmonary embolism in one), and patient refusal
in one.
Response and Survival
All 30 patients enrolled in the study were assessable for
response and survival analyses. In the first step of the trial,
one patient responded to the treatment, and then the trial
proceeded to the second step. Overall, only this objective
tumor response was observed, with a response rate of 3.3%
(95% confidence interval: 0–10.2%), whereas 18 patients
(60.0%) achieved stable disease (95% confidence interval:
41.4–78.6%). In this responder (an 82-year-old woman with
adenocarcinoma who had never smoked), the mutation status
of the EGFR tyrosine kinase domain (exons 18–21) in her
tumor specimen obtained by transbronchial biopsy was reex-
amined using the same detection method. Nevertheless, no
patterns of mutations were detected.
Survival curves of the 30 patients are displayed in
Figure 1. With a median follow-up time of 10.7 months, 28
(90%) of patients experienced disease progression or died.
The median survival time (MST) and median PFS were 9.2
months (95% confidence interval: 7.5–11.2 months) and 2.1
months (95% confidence interval: 1.4–3.0 months), respec-
tively. We also analyzed the patient survival according to the
several clinical characteristics, including tumor histology,
smoking status, and gender. As can be seen in Figure 2,
among several subpopulations, PFS seemed superior in the
patients without any smoking history (PFS time of 4.3
months). The female patients and those without any smoking
history had a relatively better overall survival (MST: not
reached and 12.9 months, respectively), despite the small
sample size.
Poststudy treatment was conducted in 20 patients
(67%), majority (14 patients) of which was single-agent
therapy including vinorelbine, S1 (newly developed oral
5-fluorouracil derivative), gemcitabine, and docetaxel.
Safety
The adverse event profile is shown in Table 2. The most
common adverse event was skin rash (97%), which mainly
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FIGURE 1. Survival curves of the 30 patients. Bold and
thin lines indicate progression-free survival and overall sur-
vival, respectively.
TABLE 1. Patient Characteristics
Number of patients 30
Age (yr)
Median (range) 67 (35–88)
Gender
Male 24
Female 6
Smoking status
Current/former/never 8/16/6
Performance status
0/1/2 7/19/4
Histology
Adenocarcinoma 20
Squamous cell carcinoma 7
Adenosquamous cell carcinoma 1
Unclassified 2
Stage
IIIB 5
IV 14
Postoperative recurrence 11
No. of prior chemotherapy regimens
1/2/3 14/12/4
Time interval between the date of final administration of
prior chemotherapy and the registration (wk)
Median (range) 11 (4–51)
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developed in the face. Nevertheless, all skin toxicities were
well tolerated and reversible with either an appropriate treat-
ment interruption or dose reduction without any treatment
discontinuation as described above. One patient developed
grade 4 pulmonary embolism on day 67. He recovered suc-
cessfully with the discontinuation of erlotinib and the subse-
quent warfarin therapy. We could not rule out the possibility
that erlotinib directly affected the occurrence of the event.
Two other patients developed ILD (grade 2 on day 28 and
grade 1 on day 15). In these cases, congestive heart failure
and infection were clinically excluded in the absence of
typical subjective symptoms such as high fever and edema, in
addition to the diagnostic radiologists’ reviews of chest
x-rays and CTs. Progression of lung cancer was also
eliminated by a review of clinical symptoms and serial
chest radiographs or CT scans. Both events of ILD were
judged, clinically and radiologically, to be possibly related
to erlotinib, although bronchoalveolar lavage or lung bi-
opsy was not performed. Both patients responded well to
steroid therapy. One patient developed grade 4 keratitis on
day 22 with conjunctival congestion and ophthalmalgia,
with no decrease in visual acuity. Although he had no
history of significant corneal epithelial disease or use of
contact lenses, this event was considered to be possibly
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FIGURE 2. Survival curves according to the clinical characteristics. Bold and thin lines indicate progression-free survival
curve and overall survival, respectively. A, Patients with adenocarcinoma (median survival time and median progression-free
survival curve of 8.6 and 2.1 months, respectively). B, Patients with other histology (10.1 and 1.9 months). C, Patients with
smoking history (8.6 and 1.9 months). D, Patients without any smoking history (12.9 and 4.3 months). E, Male patients (8.6
and 2.0 months). F, Female patients (not reached and 2.1 months).
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related to erlotinib. The treatment was discontinued and
appropriate supportive care was administered, which led to
an immediate recovery. One patient experienced hemato-
logical toxicity (grade 3 anemia), whereas leukopenia and
thrombocytopenia were not observed. This event was grad-
ually exacerbated on a monthly basis, and no hemorrhage
was detected. Cancer cachexia was also observed at the
same time, and thus this adverse event was unlikely to
have been directly related to the erlotinib therapy. In total,
no treatment-related deaths occurred.
DISCUSSION
This is the first prospective biomarker study to evaluate
erlotinib therapy in pretreated patients with EGFR-wt tumors.
In this study, we found an objective response rate of 3.3%, a
median PFS time of 2.1 months, and a MST of 9.2 months,
along with manageable and nonfatal adverse events, mainly
skin rashes.
To date, several studies have reported efficacy data for
relapsed patients with EGFR-wt tumors in the subgroup
analysis of phase III trials (Table 3).1,7,11 In those patients
treated with erlotinib, gefitinib, or docetaxel monotherapy,
the response rate, median PFS time, and MST were less than
10%, around 2 months, and 6 to 8 months, respectively.
Looking at our current data, the objective response rate, the
primary end point of our study, was lower than we initially
expected. Thus, strictly speaking, the trial did not meet the
primary end point, but considering other efficacy data includ-
ing PFS and overall survival, the secondary end point, erlo-
tinib therapy for pretreated patients with EGFR-wt tumors,
seems to be similarly efficacious to these existing retrospec-
tive data.
We found that the major adverse event was skin rash,
which affected 23% (grade 3; seven patients) of the whole
cohort. The incidence was higher than previously reported
(9%).2 This difference might have been attributable to a
difference in patient populations, a difference in follow-up
pattern, and/or ethnic differences. In our cohort, all these
events improved with short-term interruption of erlotinib or
dose reduction, and none of the seven patients withdrew the
treatment directly because of the skin toxicity. Thus, although
this was the most frequent adverse event, it was reasonably
well tolerated.
Regarding ILD after the initiation of gefitinib, we
retrospectively studied a cohort of 330 patients with NSCLC
and demonstrated an overall ILD incidence of 4.5%, with a
mortality rate of 2.4%.12 In the current prospective trial, 2
patients (6.7%) developed ILD (grades 1 and 2 in one each),
supporting an almost similar frequency but milder grades in
erlotinib therapy. The incidences of ILD in our retrospective
analysis and our current study were higher than those ob-
tained in other reports (i.e., the BR.21 trial reported its
incidence of pneumonitis or pulmonary infiltrates to be less
than 1%).2,13 Differences in diagnostic criteria for ILD and
genetic variability between Japanese and others might have
contributed to this difference. The ILD data in this study were
indeed preliminary because of the small cohort, and thus
further extensive epidemiological research must be conducted
to clarify this issue.
One of the 30 patients responded to erlotinib therapy.
No mutations were detected in her tumor specimen, which
was examined twice with the clamp method. This finding
might be interpreted in the following manner: a possible
false-negative result (sensitivity and specificity of the clamp
method: 89% and 100%, respectively14), the presence of
unknown active mutations in other exons of EGFR genes, and
the presence of other potential pathway related to antitumor
activity rather than the EGFR pathway. We cannot further
determine which explanation would be more likely. Among
them, the possibility of a false-negative might lead to a major
limitation of our study, and other sensitive detection methods
such as the Scorpion Amplified Refractory Mutation System
assay15 would have to be applied in such a patient cohort.
TABLE 2. Adverse Events
Toxicity
No. of Patients
Grades 1 2 3 4
Skin rash 7 (23%) 15 (50%) 7 (23%) 0
Diarrhea 12 (40%) 3 (10%) 0 0
Nausea/vomiting 7 (23%) 0 2 (7%) 0
Liver injury 7 (23%) 2 (7%) 0 0
Dysgeusia 2 (7%) 0 0 0
Interstitial lung disease 1 (3%) 1 (3%) 0 0
Anemia 0 0 1 (3%) 0
Pulmonary infarction 0 0 0 1 (3%)
Keratitis 0 0 0 1 (3%)
No patients died of adverse events.
TABLE 3. Efficacy of Various Chemotherapy Treatment in Relapsed Patients with EGFR-wt Tumors in Representative Phase III
Trials
Authors Country Year No. of Patients Regimens Drug Dose ORR (%) MPFS (mo) MST (mo)
Hirsch et al.11 USA 2006 116 Gefitinib 250 mg/d 2.6 NR NR
Zhu et al.7 Canada 2008 115 Erlotinib 150 mg/d 6.9 NR 7.9
55 Placebo — — NR 3.3
Kim et al.1 France 2008 106 Gefitinib 250 mg/d 6.6 1.7 6.4
123 Docetaxel 75 mg/m2 9.8 2.6 6.0
Current study Japan 2009 30 Erlotinib 150 mg/d 3.3 2.1 9.2
EGFR-wt, epidermal growth factor receptor-wild-type; ORR, objective response rate; MPFS, median progression-free survival; MST, median survival time; NR, not recorded.
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Finally, this phenomenon suggests that physicians should be
aware that a patient could respond well to the TKI therapy,
even though his or her mutation analysis reveals a “mutant-
negative” result.
In conclusion, erlotinib therapy for pretreated patients
with EGFR-wt tumors seemed to be similarly efficacious to
the existing data with no fatal toxicities. These results might
support the use of erlotinib even in patients who do not
possess EGFR-mt tumors, although further studies in this
patient setting are warranted.
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